Genexine, Inc. (KOSDAQ:095700)

South Korea flag South Korea · Delayed Price · Currency is KRW
5,070.00
-100.00 (-1.93%)
Oct 30, 2025, 3:30 PM KST
-1.93%
Market Cap230.58B
Revenue (ttm)5.81B
Net Income (ttm)-54.53B
Shares Out45.48M
EPS (ttm)-1,320.62
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume256,808
Average Volume280,776
Open5,170.00
Previous Close5,170.00
Day's Range5,050.00 - 5,250.00
52-Week Range3,510.00 - 8,130.00
Beta0.63
RSI42.52
Earnings DateAug 14, 2025

About Genexine

Genexine, Inc., together with its subsidiaries, operates as a biotechnology company that focuses on the development and commercialization of immunotherapies in South Korea and internationally. The company develops its products through its hybrid Fc platform, a proprietary technology designed to develop long-acting protein drugs; and the DNA vaccine platform that is used to elicit immune responses in the human body to fight viral infection and cancer cells. Its product pipeline includes GX-H9, which is in Phase II and III clinical trials for the... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 86
Stock Exchange KOSDAQ
Ticker Symbol 095700
Full Company Profile

Financial Performance

In 2023, Genexine's revenue was 4.43 billion, a decrease of -72.57% compared to the previous year's 16.14 billion. Losses were -66.87 billion, 19.5% more than in 2022.

Financial Statements

News

There is no news available yet.